Group cognitive behavioral therapy integrated with usual care for adults with ADHD and substance use disorder
Official title: Adults With Attention Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment: Effectiveness and Feasibility
Run by Assistance Publique - Hôpitaux de Paris · NCT06858527 · Data updated 2026-11-12
This program will test whether adding group cognitive behavioral therapy to usual care helps adults who have both ADHD and a moderate-to-severe substance use disorder.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 132 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | July 2029 |
| Study ends | July 2029 |
| Registry record updated | June 26, 2025 |
| Trial ID | NCT06858527 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who speak French, are insured, have a DSM-5 moderate-to-severe substance use disorder (not limited to tobacco), have an ADHD diagnosis by DIVA, are currently receiving SUD treatment, and can provide informed consent are eligible.
✕Probably not a fit
People with only tobacco use disorder, severe cognitive impairment, inability to understand French, current confinement or recent protected environment for substance use, pregnancy/breastfeeding, or who cannot attend in-person group sessions are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a longitudinal, randomized controlled crossover study comparing an integrated group cognitive behavioral therapy (CBT) intervention with treatment-as-usual (TAU) using a waitlist design. Adults diagnosed with ADHD by DIVA and a moderate-to-severe substance use disorder (excluding tobacco) who are already in SUD care will be enrolled and randomized. Participants receive group CBT in addition to their usual care or remain on a TAU waitlist before crossing over to the intervention, with outcomes measured over time. The study is conducted in person at Hôpital Fernand Widal in Paris and uses standardized diagnostic criteria and structured group psychotherapy sessions.
Why it matters
Potential benefit: If successful, the intervention could reduce substance use and improve ADHD symptoms and daily functioning by providing a structured, integrated psychotherapy option.
How similar studies have gone: CBT is well supported for substance use disorders and integrated approaches are recommended for ADHD-SUD comorbidity, but randomized trials of structured group CBT specifically for this combined population remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older ; * Suffer from at least one moderate to severe SUD regarding the DSM-5 (tobacco excluded) ; * Being currently treated for a SUD by a physician of a psychologist ; * Being diagnosed with an ADHD according to the DIVA 2.0 of DIVA-5 ; * Being affiliated to a health insurance ; * Understanding and being able to express himselves in French * Signed consent Exclusion Criteria: * Age under 18; * Pregnant or breastfeeding women; * Not having sign the consent form; * Major difficulties in understanding and/or expressing themselves in french; * Severe cognitive impairment; * Acute medical condition making assessment impossible and/or contraindicating participation in group intervention; * Substance use disorder in a protected environment, currentlu or in the last 15 days, or expected during the study; * No substance use disorder other than tobacco use disorder; * Persons under guardianship; * Participant deprived of liberty or under penal care orders; * Participation in another group psychotherapeutic intervention throughout the duration of the intervention
Where it's running
-
Hôpital Fernand Widal, Assistance-Publique - Hôpitaux de Paris
Paris, France Recruiting
Study contacts
- Principal investigator: Norman Therribout, PhD — Paris-Nanterre University, UR-4430 CLIPSYD ; Paris-Cité University, UMR-S-1144 INSERM; Fernand-Widal Hospital AP-HP
- Study coordinator: Norman Therribout, PhD
- Email: norman.therribout@aphp.fr
- Phone: +33140054464
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Micronutrient and Chronotherapy for ADHD in children ages 6-12
This 12-week trial tests whether a broad-spectrum vitamin/mineral supplement plus guidance on sleep and meal timing can help reduce ADHD symptoms in children aged 6–12.
-
The ENHANCE Project Toolkit
This pilot study tests a bundle of smartphone and online tools to help people who use drugs reduce overdose risk.
-
Home-based brain-controlled game therapy for children with ADHD
This study will test whether home-based brain-controlled game therapy can help reduce core ADHD symptoms in children aged 7 to 11 with mild to moderate ADHD.
-
Probiotics for children with ADHD: gut-brain axis impact
This study tests whether daily probiotics help kids with ADHD by influencing the gut-brain connection, compared with a placebo.
-
Predicting ADHD in middle-school children from foot pressure and posture measurements
Researchers will try to see if foot pressure and posture measurements can help predict ADHD in middle-school-aged children.
-
Virtual reality and simulator training to reduce distracted driving in teens with ADHD
This program will test two training approaches—one using virtual reality and one using a driving simulator—to help licensed teens with ADHD keep their eyes on the road and reduce crash risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.